Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 22 entries
Sorted by: Best Match Show Resources per page
Risk factors, diagnosis, and detection of melanoma.

Current opinion in oncology

MacKie RM.
PMID: 2069997
Curr Opin Oncol. 1991 Apr;3(2):360-3. doi: 10.1097/00001622-199104000-00019.

The incidence of melanoma continues to rise, and accurate figures for this rate of rise in subsets of the population are needed. In addition, it is important to identify occupational groups possibly at greater risk, as well as phenotypic...

Cite
MacKie RM. Risk factors, diagnosis, and detection of melanoma. Curr Opin Oncol. 1991;3(2):360-3doi: 10.1097/00001622-199104000-00019.
MacKie, R. M. (1991). Risk factors, diagnosis, and detection of melanoma. Current opinion in oncology, 3(2), 360-3. https://doi.org/10.1097/00001622-199104000-00019
MacKie, R M. "Risk factors, diagnosis, and detection of melanoma." Current opinion in oncology vol. 3,2 (1991): 360-3. doi: https://doi.org/10.1097/00001622-199104000-00019
MacKie RM. Risk factors, diagnosis, and detection of melanoma. Curr Opin Oncol. 1991 Apr;3(2):360-3. doi: 10.1097/00001622-199104000-00019. PMID: 2069997.
Copy Download .nbib Format: NLM
Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification.

In vivo (Athens, Greece)

Rastrelli M, Tropea S, Rossi CR, Alaibac M.
PMID: 25398793
In Vivo. 2014 Nov-Dec;28(6):1005-11.

This article reviews epidemiology, risk factors, pathogenesis and diagnosis of melanoma. Data on melanoma from the majority of countries show a rapid increase of the incidence of this cancer, with a slowing of the rate of incidence in the...

Cite
Rastrelli M, Tropea S, Rossi CR, et al. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014;28(6):1005-11
Rastrelli, M., Tropea, S., Rossi, C. R., & Alaibac, M. (2014). Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In vivo (Athens, Greece), 28(6), 1005-11.
Rastrelli, Marco, et al. "Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification." In vivo (Athens, Greece) vol. 28,6 (2014): 1005-11.
Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014 Nov-Dec;28(6):1005-11. PMID: 25398793.
Copy Download .nbib Format: NLM
Understanding melanoma.

Imprint

[No authors listed]
PMID: 9505598
Imprint. 1998 Jan;45(1):14.

No abstract available.

Cite
Understanding melanoma. Imprint. 1998;45(1):14
(1998). Understanding melanoma. Imprint, 45(1), 14.
"Understanding melanoma." Imprint vol. 45,1 (1998): 14.
Understanding melanoma. Imprint. 1998 Jan;45(1):14. PMID: 9505598.
Copy Download .nbib Format: NLM
Malignant melanoma.

The British journal of dermatology

Bodenham DC.
PMID: 5646070
Br J Dermatol. 1968 Mar;80(3):190-2. doi: 10.1111/j.1365-2133.1968.tb12291.x.

No abstract available.

Cite
Bodenham DC. Malignant melanoma. Br J Dermatol. 1968;80(3):190-2doi: 10.1111/j.1365-2133.1968.tb12291.x.
Bodenham, D. C. (1968). Malignant melanoma. The British journal of dermatology, 80(3), 190-2. https://doi.org/10.1111/j.1365-2133.1968.tb12291.x
Bodenham, D C. "Malignant melanoma." The British journal of dermatology vol. 80,3 (1968): 190-2. doi: https://doi.org/10.1111/j.1365-2133.1968.tb12291.x
Bodenham DC. Malignant melanoma. Br J Dermatol. 1968 Mar;80(3):190-2. doi: 10.1111/j.1365-2133.1968.tb12291.x. PMID: 5646070.
Copy Download .nbib Format: NLM
[Malignant melanoma].

La Revue du praticien

Delaunay M.
PMID: 7660014
Rev Prat. 1995 Jun 15;45(12):1561-6.

No abstract available.

Cite
Delaunay M. Mélanomes malins. [Malignant melanoma]. Rev Prat. 1995;45(12):1561-6
Delaunay, M. (1995). Mélanomes malins. [Malignant melanoma]. La Revue du praticien, 45(12), 1561-6.
Delaunay, M. "Mélanomes malins." [Malignant melanoma]. La Revue du praticien vol. 45,12 (1995): 1561-6.
Delaunay M. Mélanomes malins. [Malignant melanoma]. Rev Prat. 1995 Jun 15;45(12):1561-6. French. PMID: 7660014.
Copy Download .nbib Format: NLM
Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis.

Medicine

Feng S, Zhou L, Liu Q, He Q, Liao B, Wei X, Li H, Wang K, Zhu Y.
PMID: 29504984
Medicine (Baltimore). 2018 Jan;97(3):e9601. doi: 10.1097/MD.0000000000009601.

Phosphodiesterase type 5 (PDE5) inhibitors are recommended for patients with erectile dysfunction by American Urological Association and European Association Urology guidelines. However, recent researches have shown that PDE5 inhibitors may lead to increased melanoma risk. Thus, we aimed to...

Cite
Feng S, Zhou L, Liu Q, et al. Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis. Medicine (Baltimore). 2018;97(3):e9601doi: 10.1097/MD.0000000000009601.
Feng, S., Zhou, L., Liu, Q., He, Q., Liao, B., Wei, X., Li, H., Wang, K., & Zhu, Y. (2018). Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis. Medicine, 97(3), e9601. https://doi.org/10.1097/MD.0000000000009601
Feng, Shijian, et al. "Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis." Medicine vol. 97,3 (2018): e9601. doi: https://doi.org/10.1097/MD.0000000000009601
Feng S, Zhou L, Liu Q, He Q, Liao B, Wei X, Li H, Wang K, Zhu Y. Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis. Medicine (Baltimore). 2018 Jan;97(3):e9601. doi: 10.1097/MD.0000000000009601. PMID: 29504984; PMCID: PMC5779753.
Copy Download .nbib Format: NLM
Multiple primary melanoma: a single centre retrospective review.

Melanoma research

Menzies S, Barry R, Ormond P.
PMID: 29076952
Melanoma Res. 2017 Dec;27(6):638-640. doi: 10.1097/CMR.0000000000000395.

Prognosis has been shown to be worse for patients with multiple primary melanomas than those with a single melanoma. One recent retrospective study showed that older, white men were at higher risk of multiple primary melanomas. In our institution...

Cite
Menzies S, Barry R, Ormond P. Multiple primary melanoma: a single centre retrospective review. Melanoma Res. 2017;27(6):638-640doi: 10.1097/CMR.0000000000000395.
Menzies, S., Barry, R., & Ormond, P. (2017). Multiple primary melanoma: a single centre retrospective review. Melanoma research, 27(6), 638-640. https://doi.org/10.1097/CMR.0000000000000395
Menzies, Stephanie, et al. "Multiple primary melanoma: a single centre retrospective review." Melanoma research vol. 27,6 (2017): 638-640. doi: https://doi.org/10.1097/CMR.0000000000000395
Menzies S, Barry R, Ormond P. Multiple primary melanoma: a single centre retrospective review. Melanoma Res. 2017 Dec;27(6):638-640. doi: 10.1097/CMR.0000000000000395. PMID: 29076952.
Copy Download .nbib Format: NLM
Pattern of melanoma incidence in Miami, Florida.

Journal of the National Medical Association

Aldrich TE, Garcia N.
PMID: 7277525
J Natl Med Assoc. 1981 Sep;73(9):887-8.

Although melanoma causes only 1.4 percent of cancers nationally, it accounts for 3.6 percent of cancers in southern Flordia. The authors conducted an incidence survey to determine if the distribution of melanoma was a function of population density, an...

Cite
Aldrich TE, Garcia N. Pattern of melanoma incidence in Miami, Florida. J Natl Med Assoc. 1981;73(9):887-8
Aldrich, T. E., & Garcia, N. (1981). Pattern of melanoma incidence in Miami, Florida. Journal of the National Medical Association, 73(9), 887-8.
Aldrich, T E, and Garcia, N. "Pattern of melanoma incidence in Miami, Florida." Journal of the National Medical Association vol. 73,9 (1981): 887-8.
Aldrich TE, Garcia N. Pattern of melanoma incidence in Miami, Florida. J Natl Med Assoc. 1981 Sep;73(9):887-8. PMID: 7277525; PMCID: PMC2552735.
Copy Download .nbib Format: NLM
Metastatic signet-ring cell melanoma.

Journal of the American Academy of Dermatology

Botev IN.
PMID: 8349882
J Am Acad Dermatol. 1993 Sep;29(3):510-1. doi: 10.1016/s0190-9622(08)82025-7.

No abstract available.

Cite
Botev IN. Metastatic signet-ring cell melanoma. J Am Acad Dermatol. 1993;29(3):510-1doi: 10.1016/s0190-9622(08)82025-7.
Botev, I. N. (1993). Metastatic signet-ring cell melanoma. Journal of the American Academy of Dermatology, 29(3), 510-1. https://doi.org/10.1016/s0190-9622(08)82025-7
Botev, I N. "Metastatic signet-ring cell melanoma." Journal of the American Academy of Dermatology vol. 29,3 (1993): 510-1. doi: https://doi.org/10.1016/s0190-9622(08)82025-7
Botev IN. Metastatic signet-ring cell melanoma. J Am Acad Dermatol. 1993 Sep;29(3):510-1. doi: 10.1016/s0190-9622(08)82025-7. PMID: 8349882.
Copy Download .nbib Format: NLM
[Difficult-to-diagnose melanomas: a key role for the dermatologist].

Annales de dermatologie et de venereologie

Mortier L, Lin PY, Chai CS, Jong MSY, Dai Y.
PMID: 25442468
Ann Dermatol Venereol. 2014 Nov;141(11):653-4. doi: 10.1016/j.annder.2014.09.016. Epub 2014 Oct 18.

No abstract available.

Cite
Mortier L, Lin PY, Chai CS, et al. Mélanomes difficiles à diagnostiquer : un rôle clé pour le dermatologue… [Difficult-to-diagnose melanomas: a key role for the dermatologist]. Ann Dermatol Venereol. 2014;141(11):653-4doi: 10.1016/j.annder.2014.09.016.
Mortier, L., Lin, P. Y., Chai, C. S., Jong, M. S. Y., & Dai, Y. (2014). Mélanomes difficiles à diagnostiquer : un rôle clé pour le dermatologue… [Difficult-to-diagnose melanomas: a key role for the dermatologist]. Annales de dermatologie et de venereologie, 141(11), 653-4. https://doi.org/10.1016/j.annder.2014.09.016
Mortier, L, et al. "Mélanomes difficiles à diagnostiquer : un rôle clé pour le dermatologue…" [Difficult-to-diagnose melanomas: a key role for the dermatologist]. Annales de dermatologie et de venereologie vol. 141,11 (2014): 653-4. doi: https://doi.org/10.1016/j.annder.2014.09.016
Mortier L, Lin PY, Chai CS, Jong MSY, Dai Y. Mélanomes difficiles à diagnostiquer : un rôle clé pour le dermatologue… [Difficult-to-diagnose melanomas: a key role for the dermatologist]. Ann Dermatol Venereol. 2014 Nov;141(11):653-4. doi: 10.1016/j.annder.2014.09.016. Epub 2014 Oct 18. French. PMID: 25442468.
Copy Download .nbib Format: NLM
Melanoma Risk Estimation Based on Objective Measures as a Complement to Self-Assessment.

Anticancer research

Carlsson A, Falk M.
PMID: 32487628
Anticancer Res. 2020 Jun;40(6):3325-3331. doi: 10.21873/anticanres.14315.

BACKGROUND/AIM: A variety of self-tests addressing individual skin cancer risk are available online. These are generally based on self-estimated measures, such as self-rated skin sensitivity to sun exposure, affecting its reliability. The aim of this study was to investigate...

Cite
Carlsson A, Falk M. Melanoma Risk Estimation Based on Objective Measures as a Complement to Self-Assessment. Anticancer Res. 2020;40(6):3325-3331doi: 10.21873/anticanres.14315.
Carlsson, A., & Falk, M. (2020). Melanoma Risk Estimation Based on Objective Measures as a Complement to Self-Assessment. Anticancer research, 40(6), 3325-3331. https://doi.org/10.21873/anticanres.14315
Carlsson, Adam, and Falk, Magnus. "Melanoma Risk Estimation Based on Objective Measures as a Complement to Self-Assessment." Anticancer research vol. 40,6 (2020): 3325-3331. doi: https://doi.org/10.21873/anticanres.14315
Carlsson A, Falk M. Melanoma Risk Estimation Based on Objective Measures as a Complement to Self-Assessment. Anticancer Res. 2020 Jun;40(6):3325-3331. doi: 10.21873/anticanres.14315. PMID: 32487628.
Copy Download .nbib Format: NLM
Melanoma: epidemiology, pathogenesis, and new modes of treatment.

Advances in internal medicine

Dreiling L, Hoffman S, Robinson WA.
PMID: 8903599
Adv Intern Med. 1996;41:553-604.

The treatment of patients with advanced stage (stage III and IV) melanoma remains discouraging. Except for the study using tamoxifen, combination chemotherapy (cisplatin, DTIC, BCNU), plus biological therapy (IFN-alpha and/or IL-2), which achieved a 57% response rate, virtually any...

Cite
Dreiling L, Hoffman S, Robinson WA. Melanoma: epidemiology, pathogenesis, and new modes of treatment. Adv Intern Med. 1996;41:553-604
Dreiling, L., Hoffman, S., & Robinson, W. A. (1996). Melanoma: epidemiology, pathogenesis, and new modes of treatment. Advances in internal medicine, 41553-604.
Dreiling, L, et al. "Melanoma: epidemiology, pathogenesis, and new modes of treatment." Advances in internal medicine vol. 41 (1996): 553-604.
Dreiling L, Hoffman S, Robinson WA. Melanoma: epidemiology, pathogenesis, and new modes of treatment. Adv Intern Med. 1996;41:553-604. PMID: 8903599.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 22 entries